Form 4: Natera Co-Founder Sells Shares for Tax Obligations

Jonathan Sheena, Natera's Co-Founder and Director, sold shares totaling 482 units to cover tax obligations related to RSU vesting under a Rule 10b5-1 plan.

Summary

• Jonathan Sheena, Co-Founder and Director of Natera, Inc. (NTRA), reported sales of common stock.
• On January 27, 2026, 291 shares were sold at a price of $240.5313 per share.
• On January 28, 2026, an additional 191 shares were sold at a price of $237.6624 per share.
• These sales were executed to satisfy tax withholding and remittance obligations associated with the vesting of Restricted Stock Units (RSUs).
• The transactions were conducted pursuant to a written instruction intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.
• Following these transactions, Sheena directly beneficially owns 263,596 shares of common stock.
• Additionally, 21,782 shares are indirectly owned by Caraluna 1 Trust and another 21,782 shares by Caraluna 2 Trust.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a largely neutral event. While it's a sale by an insider, it's explicitly for tax purposes under a pre-arranged plan, which mitigates negative sentiment often associated with insider selling.

Positives

• The sales were made pursuant to a Rule 10b5-1(c) plan, indicating pre-planned transactions and reducing concerns about opportunistic insider selling.
• The sales were specifically for tax withholding obligations related to RSU vesting, which is a common and routine event for executives receiving equity compensation.

Negatives

• A director and co-founder sold a total of 482 shares of common stock.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that tax-related sales by executives, particularly those under Rule 10b5-1 plans, are a routine occurrence across the biotechnology and broader healthcare sectors. These transactions typically do not reflect a change in management's outlook on the company's prospects but rather a mechanism to cover tax liabilities arising from equity compensation.

Stakeholder Impact

• Shareholders: Minor dilution from the sale of shares, but the impact is negligible given the small volume relative to total outstanding shares. The transparency of the 10b5-1 plan provides clarity.

Key Dates

Recommendation

The filing details routine insider stock sales for tax purposes under a pre-arranged 10b5-1 plan. This type of transaction is common and generally does not indicate a change in the company's fundamentals or management's long-term outlook. Therefore, it does not provide sufficient new information to warrant a change in investment recommendation, suggesting a 'hold' position for existing investors.

Keywords

Natera, NTRA, Form 4, Insider Trading, Stock Sale, RSU Vesting, Tax Obligations, Jonathan Sheena, 10b5-1 Plan, Biotechnology, Healthcare